Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.

Fredrikson S, McLeod E, Henry N, Pitcher A, Lowin J, Cuche M, Fajutrao L, Perard R, Bates D, Chan A.

J Med Econ. 2013;16(6):756-62. doi: 10.3111/13696998.2013.792824. Epub 2013 Apr 17.

PMID:
23556422
[PubMed - indexed for MEDLINE]
2.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

PMID:
19739877
[PubMed - indexed for MEDLINE]
Free Article
3.

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.

Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.

J Med Econ. 2012;15(6):1088-96. doi: 10.3111/13696998.2012.693553. Epub 2012 May 24.

PMID:
22583065
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.

Janković SM, Kostić M, Radosavljević M, Tesić D, Stefanović-Stoimenov N, Stevanović I, Raković S, Aleksić J, Folić M, Aleksić A, Mihajlović I, Biorac N, Borlja J, Vucković R.

Vojnosanit Pregl. 2009 Jul;66(7):556-62.

PMID:
19678581
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.

J Manag Care Pharm. 2007 Apr;13(3):245-61.

PMID:
17407391
[PubMed - indexed for MEDLINE]
Free Article
6.

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.

Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R.

J Med Econ. 2012;15(3):424-33. doi: 10.3111/13696998.2012.654868. Epub 2012 Jan 27.

PMID:
22217249
[PubMed - indexed for MEDLINE]
7.

Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.

Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl C, Hartung HP, Shah D, Miller JD, Sandbrink R, Lanius V, Gondek K, Russell MW.

Clin Ther. 2012 May;34(5):1132-44. doi: 10.1016/j.clinthera.2012.03.004. Epub 2012 Apr 27.

PMID:
22541587
[PubMed - indexed for MEDLINE]
8.

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.

Sanford M, Lyseng-Williamson KA.

Drugs. 2011 Oct 1;71(14):1865-91. doi: 10.2165/11207540-000000000-00000. Review.

PMID:
21942977
[PubMed - indexed for MEDLINE]
9.

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.

Kobelt G, Jönsson L, Henriksson F, Fredrikson S, Jönsson B.

Int J Technol Assess Health Care. 2000 Summer;16(3):768-80.

PMID:
11028132
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.

Nuijten MJ, Hutton J.

Value Health. 2002 Jan-Feb;5(1):44-54.

PMID:
11873383
[PubMed - indexed for MEDLINE]
11.

Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Guo S, Bozkaya D, Ward A, O'Brien JA, Ishak K, Bennett R, Al-Sabbagh A, Meletiche DM.

Pharmacoeconomics. 2009;27(1):39-53. doi: 10.2165/00019053-200927010-00005.

PMID:
19178123
[PubMed - indexed for MEDLINE]
12.

Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.

Traboulsee A, Al-Sabbagh A, Bennett R, Chang P, Li DK; EVIDENCE Study Group; UBC MS/MRI Research Group.

BMC Neurol. 2008 Apr 21;8:11. doi: 10.1186/1471-2377-8-11.

PMID:
18426595
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.

Kendrick M, Johnson KI.

Pharmacoeconomics. 2000 Jul;18(1):45-53. Review.

PMID:
11010603
[PubMed - indexed for MEDLINE]
14.

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.

Nuijten M, Mittendorf T.

Clin Ther. 2010 Apr;32(4):717-28. doi: 10.1016/j.clinthera.2010.03.019.

PMID:
20435242
[PubMed - indexed for MEDLINE]
15.

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L.

Lancet Neurol. 2012 Jan;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9. Epub 2011 Dec 4. Erratum in: Lancet Neurol. 2012 Feb;11(2):125.

PMID:
22146409
[PubMed - indexed for MEDLINE]
16.
17.

Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Pan F, Goh JW, Cutter G, Su W, Pleimes D, Wang C.

Clin Ther. 2012 Sep;34(9):1966-76. doi: 10.1016/j.clinthera.2012.07.010. Epub 2012 Aug 18.

PMID:
22906738
[PubMed - indexed for MEDLINE]
18.

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J.

Pharmacoeconomics. 2008;26(7):617-27.

PMID:
18563952
[PubMed - indexed for MEDLINE]
19.

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

Kobelt G, Jönsson L, Miltenburger C, Jönsson B.

Int J Technol Assess Health Care. 2002 Winter;18(1):127-38.

PMID:
11987436
[PubMed - indexed for MEDLINE]
20.

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.

Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC.

Value Health. 2004 Sep-Oct;7(5):554-68.

PMID:
15367251
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk